Eosinophilic esophagitis is a chronic immune/antigen-mediated disease characterized by eosinophil infiltration of the esophageal epithelium resulting in symptoms such as dysphagia, food impaction, and abdominal pain. The disease is increasingly being recognized and requires long-term pharmacologic treatment with proton pump inhibitors or topical corticosteroids to eliminate clinical symptoms.
The global Eosinophilic Esophagitis Market is estimated to be valued at US$ 245.92 million in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The availability of targeted treatment options is accelerating the growth of the Eosinophilic Esophagitis market over the forecast period. Traditionally, topical steroids were used in the treatment of Eosinophilic Esophagitis. However, they are associated with side-effects such as nephrotoxicity, Cushingoid features. Novel targeted biologics offer promising therapeutic benefit and safer treatment options for Eosinophilic Esophagitis with minimal side-effects. For instance, benralizumab, which targets IL-5 receptor, has demonstrated meaningful histologic and symptomatic improvement in phase 3 clinical trials. With the FDA approval of targeted biologics such as benralizumab and mepolizumab, the treatment landscape for Eosinophilic Esophagitis is evolving rapidly thereby increasing market growth.
Segment Analysis
Eosinophilic Esophagitis Market is segmented based on drug class into corticosteroids, proton pump inhibitors (PPIs), and biologics. The biologics sub-segment dominates the market as biologics specifically target eosinophils for treatment. Drugs like Dupixent have received FDA approval for treating eosinophilic esophagitis and thus drive growth of this sub-segment.
Key Takeaways
The global Eosinophilic Esophagitis Market Growth is expected to witness high growth over the forecast period of 2023 to 2030. The global Eosinophilic Esophagitis Market is estimated to be valued at US$ 245.92 million in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030.
North America is expected to be the fastest growing region for the Eosinophilic Esophagitis Market owing to rising prevalence rates and strong presence of key biotech companies developing biologics in the region. The region currently dominates the global market as well.
Key players
Key players operating in the Eosinophilic Esophagitis Market are Adare Pharmaceuticals, Inc., Cipla Limited, GlaxoSmithKline PLC, and TEVA Pharmaceutical Industries Ltd.
Check below Healthcare related articles on this topic: https://www.pressreleasebulletin.com/rising-incidences-of-eosinophilic-esophagitis-to-boost-therapeutic-development/
https://filmik.in/cell-therapy-harmonizing-hope-through-the-therapeutic-rhythm-of-cellular-alchemy/
